Technological aspects of the “Probioskin” emulgel development

A. Soloviova, O. Kaliuzhnaia
{"title":"Technological aspects of the “Probioskin” emulgel development","authors":"A. Soloviova, O. Kaliuzhnaia","doi":"10.24959/nphj.22.88","DOIUrl":null,"url":null,"abstract":"Aim. To develop a rational technology of a new semisolid preparation for skin application with a probiotic component in the form of an emulgel under the conditional name “Probioskin”.\nMaterials and methods. When developing the technology the study objects were emulgel samples with selected substances – a lyophilized biomass of lactobacilli, dexpanthenol, lactic acid, and excipients – Aristoflex AVC gelling agent, propylene glycol, polysorbate-80, tocopherol, peach oil. To control the quality of the samples, the requirements of the monograph of the SPhU 2.4 on dosage forms “Semi-solid preparations for dermal use” and the general monograph of the SPhU 2.5 “Viable biotherapeutic drugs for human use” were observed.\nResults and discussion. The process of production of the “Probioskin” drug developed is carried out in the premises of purity class C according to the standard flowchart: the stage of auxiliary works, the stage of the main technological process, the stage of packaging, labeling and shipment of the finished product. The sequence of the technological stages in accordance with the technology of production of a semisolid preparation for skin application – the “Probioskin” emulgel consists of 8 stages: preparation of the raw material, preparation of an oil concentrate of a probiotic component, preparation of an aqueous concentrate of active substances, preparation of a gel base, preparation of an emulsion, packaging of tubes in packs, packaging of packs in group container. The specification for the “Probioskin” drug includes the following sections: “Description”, “Identification”, “pH”, “Uniformity”, “Mass of packaging contents”, “Microbiologicalpurity”, “Assay”. The results of control of the finished product meet the requirements of the MQC.\nConclusions. Based on the complex of physicochemical, microbiological, biopharmaceutical, technological, rheological studies, a rational technology of a semisolid preparation for skin application under the conditional name “Probioskin”in the form of an emulgel has been developed. The indicators of quality, permissible norms, methods of control and critical parameters of production of the product developed have been determined.","PeriodicalId":19221,"journal":{"name":"News of Pharmacy","volume":"86 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"News of Pharmacy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.24959/nphj.22.88","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Aim. To develop a rational technology of a new semisolid preparation for skin application with a probiotic component in the form of an emulgel under the conditional name “Probioskin”. Materials and methods. When developing the technology the study objects were emulgel samples with selected substances – a lyophilized biomass of lactobacilli, dexpanthenol, lactic acid, and excipients – Aristoflex AVC gelling agent, propylene glycol, polysorbate-80, tocopherol, peach oil. To control the quality of the samples, the requirements of the monograph of the SPhU 2.4 on dosage forms “Semi-solid preparations for dermal use” and the general monograph of the SPhU 2.5 “Viable biotherapeutic drugs for human use” were observed. Results and discussion. The process of production of the “Probioskin” drug developed is carried out in the premises of purity class C according to the standard flowchart: the stage of auxiliary works, the stage of the main technological process, the stage of packaging, labeling and shipment of the finished product. The sequence of the technological stages in accordance with the technology of production of a semisolid preparation for skin application – the “Probioskin” emulgel consists of 8 stages: preparation of the raw material, preparation of an oil concentrate of a probiotic component, preparation of an aqueous concentrate of active substances, preparation of a gel base, preparation of an emulsion, packaging of tubes in packs, packaging of packs in group container. The specification for the “Probioskin” drug includes the following sections: “Description”, “Identification”, “pH”, “Uniformity”, “Mass of packaging contents”, “Microbiologicalpurity”, “Assay”. The results of control of the finished product meet the requirements of the MQC. Conclusions. Based on the complex of physicochemical, microbiological, biopharmaceutical, technological, rheological studies, a rational technology of a semisolid preparation for skin application under the conditional name “Probioskin”in the form of an emulgel has been developed. The indicators of quality, permissible norms, methods of control and critical parameters of production of the product developed have been determined.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
“益生菌皮肤”乳剂开发的技术方面
的目标。开发一种新的用于皮肤应用的半固体制剂的合理技术,其中含有乳剂形式的益生菌成分,条件名称为“益生菌皮肤”。材料和方法。在开发该技术时,研究对象是选定物质的凝胶样品-乳酸菌,dexpanthenol,乳酸和辅料- Aristoflex AVC胶凝剂,丙二醇,聚山梨酸酯-80,生育酚,桃油。为控制样品质量,观察SPhU 2.4各论《皮肤用半固体制剂》和SPhU 2.5通用各论《人用活性生物治疗药物》对剂型的要求。结果和讨论。所开发的“益生菌皮”药物的生产过程在纯度C级的前提下按照标准流程图进行:辅助工作阶段、主要工艺流程阶段、成品包装、贴标和出货阶段。按照生产用于皮肤的半固体制剂-“益生菌皮肤”乳凝胶的技术顺序,技术阶段包括8个阶段:原料制备,益生菌成分油浓缩物制备,活性物质水浓缩物制备,凝胶基制备,乳液制备,袋装管包装,袋装组容器包装。“益生菌皮”药物的说明书包括以下部分:“描述”、“鉴定”、“pH值”、“均匀性”、“包装内容物质量”、“微生物纯度”、“测定”。成品的控制结果符合mqc的要求。结论。基于物理化学、微生物学、生物制药、技术、流变学的综合研究,开发了一种以乳状体形式应用于皮肤的半固体制剂,条件名称为“益生菌皮肤”。确定了所开发产品的质量指标、允许标准、控制方法和关键生产参数。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
The theoretical and experimental substantiation of the composition of a mouthwash Substantiation of the composition and technology for obtaining combined sustained-release tablets for the treatment of hypertension Development of conditions for sertraline isolation from biological fluids Determination of the physical and mechanical indicators of the polymer base and the optimal method of introducing active pharmaceutical ingredients into the base composition Peculiarities of the filtration process of liposomal emulsion for the production of eye drops based on a peptide complex
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1